April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Author Affiliations & Notes
  • Juan Giralt
    Hospital Clinic, Barcelona, Spain
  • Socorro Alforja
    Hospital Clinic, Barcelona, Spain
  • Johannes Keller
    Hospital Clinic, Barcelona, Spain
  • Marta Latasiewicz
    Hospital Clinic, Barcelona, Spain
  • Christian Fontecilla
    Hospital Clinic, Barcelona, Spain
  • Alfredo Adan Civera
    Hospital Clinic, Barcelona, Spain
  • Footnotes
    Commercial Relationships Juan Giralt, None; Socorro Alforja, None; Johannes Keller, None; Marta Latasiewicz, None; Christian Fontecilla, None; Alfredo Adan Civera, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1782. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Juan Giralt, Socorro Alforja, Johannes Keller, Marta Latasiewicz, Christian Fontecilla, Alfredo Adan Civera; INTRAVITREAL DEXAMETHASONE IMPLANT IN EYES WITH CHRONIC REFRACTORY DIABETIC MACULAR OEDEMA. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1782.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To describe the changes in retinal thickness(RT) and visual acuity over time in patients with clinically significant refractory diffuse diabetic macular oedema (DME) after intravitreal implant of dexamethason (OZURDEX) .

Methods: Retrospective, interventional nonrandomized case series of patients that underwent intravitreal implant of dexamethasone for chronic diabetic macular oedema refractory to previous treatment. All patients had best corrected visual acuity, slit-lamp biomicroscopy, intraocular pressure check and OCT at 1 week, 1, 3 and 6 months.

Results: We analize 33 eyes of 32 patients, 23 male and 9 female, that underwent intravitreal implant of dexamethasone. All patients had previously had treatment with either argon laser, anti-VEGF, triamcinolone or a combination of these treatments. Retinal thickness measured by OCTdecreased in all eyes. The reduction of edema was maximal in the first month and tended to be stable for more than 3 months in some cases. We observed statistically significant decrease in central macular thickness from baseline .496.6um to 294.7um (P<0.0001) in the third month, and 356.9 (p=0.0015)um in the sixth month. Visual acuity improved in some cases, but this improvement over time was not significant.

Conclusions: Intravitreal implant of dexamethason appears to be promising in the short term, for improving retinal thicknes more than visual acuity in eyes whith chronic macular oedema unresponsive to other treatments. Randomised controlled trials with longer follow up are required to define optimum treatment regimens.

Keywords: 498 diabetes • 503 drug toxicity/drug effects • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.